Stockreport
Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests
Last illumina, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations: illumina.com/company/investor-information.html
Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making SAN DIEGO & HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management.The agreement grants QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina’s MiSeq™ Dx and NextSeq™ 550Dx Systems. The agreement also includes rights for expansion of the partnership on future Illumina diagnostic (Dx) systems. Both partners are also exploring opportunities for QIAGEN to develop and market companion diagnostics based on Illumina’s TruSight Oncology (TSO) assays that enable comprehensive genomic profiling of tumor samples in immunotherapy.Illumina and QIAGEN will cooperate to commercialize a menu of c
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | ILMN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ILMN alerts
ILMN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
ILMN alerts
High impacting Illumina, Inc. news events
Weekly update
A roundup of the hottest topics
ILMN
NEWS
NEWS
- Illumina (NASDAQ:ILMN) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.[MarketBeat]
- Illumina (NASDAQ:ILMN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.[MarketBeat]
- Illumina (NASDAQ:ILMN) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d+)" rating to a "hold (c-)" rating.[MarketBeat]
- Preimplantation Genetic Testing Market Size to Reach USD 1849.38 Million by 2032 – SNS Insider [Yahoo! Finance][Yahoo! Finance]
- Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study [Yahoo! Finance][Yahoo! Finance]
- More
ILMN
SEC Filings
SEC Filings
- 11/25/25 - Form 8-K
- 11/13/25 - Form SCHEDULE
- 11/12/25 - Form 8-K
- ILMN's page on the SEC website
- More